TransCode Therapeutics, Inc.
RNAZTransCode Therapeutics is a clinical-stage biotechnology company focused on developing immuno-oncology and RNA-based therapeutics to treat high-risk and advanced cancers.
Earnings
Next report
Aug 18, 2026 (In 6 days)Competitors
By market cap
By revenue growth
Profile
TransCode Therapeutics is a clinical-stage biotechnology company focused on developing immuno-oncology and RNA-based therapeutics to treat high-risk and advanced cancers. The company utilizes its proprietary TTX drug design engine to overcome historical delivery challenges, enabling the targeting of genetic markers outside the liver, specifically within tumors and metastatic sites. Its core value proposition lies in its modular platform that can customize RNA payloads to address previously undruggable genetic targets involved in cancer progression.
A clinical-stage pioneer in non-liver RNA delivery with a modular platform capable of targeting master regulators of metastasis like miR-10b.
FAQ
- What is TransCode Therapeutics, Inc.'s market cap?
- TransCode Therapeutics, Inc. (RNAZ) has a market capitalization of $4.1M and trades on NASDAQ.
- Who are TransCode Therapeutics, Inc.'s competitors?
- TransCode Therapeutics, Inc.'s key competitors include Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals, and others. These companies compete in similar markets and product categories.
- Who does TransCode Therapeutics, Inc. partner with?
- TransCode Therapeutics, Inc.'s notable partners include Quantum Leap Health Care Collaborative, MD Anderson Cancer Center, Massachusetts General Hospital, and others.
- What subsidiaries does TransCode Therapeutics, Inc. have?
- TransCode Therapeutics, Inc.'s subsidiaries include Polynoma, LLC, ABCJ, LLC.
- Where is TransCode Therapeutics, Inc. headquartered?
- TransCode Therapeutics, Inc. is headquartered in United States of America and employs approximately 10 people. It has been publicly traded since 2021.